WOMEN&More Research into Mifepriston as a contraceptive halted
On June th, 2026 Leiden University Medical Center has discontinued the WOMEN&More study into the drug mifepriston. An interim evaluation showed that mifepriston 50 mg is not suitable as a contraceptive. The study started on April 14, 2025. In this study, researchers aimed to demonstrate that mifepristone 50 mg is an effective and safe contraceptive option.
The evaluation revealed a higher number of positive pregnancy tests and pregnancies than expected. The percentage of ectopic pregnancies, in particular, gave cause for concern.
This is very disappointing, as this drug appeared suitable for women with contraindications to existing hormonal contraception or who experienced side effects from contraception containing estrogens and/or progestogens.
14 Dutch hospitals and more than 560 women participated in the study. All participants have since been informed via their own research teams and thanked for their contribution to scientific research.
The results of the study will be published in scientific journals in due course.
Mifepriston 200 mg in combination with misoprostol is prescribed for medical abortion and in the treatment of miscarriages. The current research results concern a different mechanism of action. The use of mifepriston 200 mg for medical abortion or medical treatment of a miscarriage is extremely safe and effective.